This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 combination therapy in patients with locally advanced or metastatic urothelial carcinoma.
All subjects voluntarily participated in the study and signed informed consent;
Male or female aged ≥18 years and ≤75 years;
Expected survival time ≥3 months;
ECOG 0-1;
Prior ADC recipients with TOPI inhibitors as toxin;
Palliative radiotherapy within 2 weeks before the first dose;
Prior immunotherapy with grade ≥3 irAE or grade ≥2 immune-related myocarditis;
Use of an immunomodulatory drug within 14 days before the first dose of study drug;
Sichuan Baili Pharmaceutical Co., Ltd.
Lead sponsor
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Collaborator